Golden Pine Ventures, founded in 2004 in Research Triangle Park, North Carolina, focuses on biotechnology and biomedical investments. The firm seeks out state-of-the-art technologies developed by leading researchers, aiming to transform them into substantial businesses. Their investment strategy targets revolutionary technologies they consider "golden pines" in the biotech landscape.
The firm's portfolio includes Kylin Therapeutics, which has raised $2 million. Golden Pine Ventures' management and directors bring extensive experience in identifying and nurturing promising biotech ventures. They offer value-added services to portfolio companies, leveraging their expertise to grow early-stage technologies into successful businesses in the biotechnology and biomedical sectors.
Portfolio Snapshot
Observed round participation, including acquisitions and grants. Current holdings, investor exits, and write-offs are not established.